LAUSR

REFERENCES 1. Hansen DL, Möller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic Anemias in Denmark, 1980-2016. Clin Epidemiol. 2020;12:497-508. https://doi.org/10. 2147/CLEP.S250250. 2. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89 (9):E150-E155. https://doi.org/10.1002/ajh.23767. 3. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936. https://doi.org/10.1182/blood-2014-06-583021. 4. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954962. https://doi.org/10.1002/pds.4233. 5. Maquet J, Derumeaux H, Lapeyre-Mestre M, Sailler L, Moulis G. Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. Eur J Intern Med. 2020;79:136-138. https://doi.org/ 10.1016/j.ejim.2020.04.030. 6. Bylsma LC, Gulbech Ording A, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980-2985. https://doi.org/10.1182/ bloodadvances.2019000476.